Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 9% Improvement Relative Risk Mortality (b) 30% late Mortality (c) 13% levels c19vitamind.com Mahmood et al. Vitamin D for COVID-19 Prophylaxis Favors vitamin D Favors control
Mahmood, 490 patient vitamin D prophylaxis study: 9% lower mortality [p=0.67] https://c19p.org/mahmood
copied to clipboard
Coronavirus in HIP Fractures CHIP 2: Is Vitamin D Deficiency Associated with Increased Mortality from COVID-19 Infections in A Hip Fracture Population?
Mahmood et al., European Journal of Medical and Health Sciences, doi:10.24018/ejmed.2021.3.6.1159
29 Dec 2021    Source   PDF   Share   Tweet
Retrospective 517 hip fracture patients in the UK with vitamin D levels measured during COVID-19 admission, not showing significant differences in mortality for supplementation in unadjusted analysis with no group details and subject to confounding by indication. There was also no significant effect based on deficiency.
risk of death, 9.4% lower, RR 0.91, p = 0.67, treatment 34 of 138 (24.6%), control 31 of 114 (27.2%), NNT 39, prescribed by GP.
risk of death, 30.5% lower, RR 0.70, p = 0.10, treatment 45 of 238 (18.9%), control 31 of 114 (27.2%), NNT 12, started after admission, late treatment result.
risk of death, 12.5% lower, RR 0.87, p = 0.51, high D levels (≥25nmol/L) 70 of 346 (20.2%), low D levels (<25nmol/L) 40 of 144 (27.8%), adjusted per study, inverted to make RR<1 favor high D levels (≥25nmol/L), cutoff ≥25nmol/L, odds ratio converted to relative risk, outcome based on serum levels.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details, substantial unadjusted confounding by indication likely.
Mahmood et al., 29 Dec 2021, retrospective, United Kingdom, peer-reviewed, 4 authors, study period 23 March, 2020 - 31 December, 2020, dosage varies.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit